Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma

作者：Reichwagen Annegret; Ziepert Marita; Kreuz Markus; Goedtel Armbrust Ute; Rixecker Tanja; Poeschel Viola; Toliat Mohammad Reza; Nuernberg Peter; Tzvetkov Mladen; Deng Shiwei; Truemper Lorenz; Hasenfuss Gerd; Pfreundschuh Michael; Wojnowski Leszek^*

来源：Pharmacogenomics, 2015, 16(4): 361-372.

DOI：10.2217/PGS.14.179

• anthracyclines
• cardiotoxicity
• clinical trial
• heart failure
• RICOVER-60
• SNP

Aim: To identify gene variants responsible for anthracycline-induced cardiotoxicity. Patients & methods: Polymorphisms of the NADPH oxidase subunits and of the anthracycline transporters ABCC1, ABCC2 and SLC28A3 were genotyped in elderly patients (61-80 years) treated for aggressive CD20(+) B-cell lymphomas with CHOP-14 with or without rituximab and followed up for 3 years. Results: The accumulation of RAC2 subunit genotypes TA/AA among cases was statistically significant upon adjustment for gender, age and doxorubicin dose in a multivariate logistic regression analysis (OR: 2.3, p = 0.028; univariate: OR: 1.8, p = 0.077). RAC2 and CYBA genotypes were significantly associated with anthracycline-induced cardiotoxicity in a meta-analysis of this and a similar previous study. Conclusion: Our results support the theory that NADPH oxidase is involved in anthracycline-induced cardiotoxicity.

• 出版日期2015
• 单位河北医科大学